CClinicalTrials.gg
CompletedNCT00245375Updated Apr 1, 2008

A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery

An interventional study of Tylenol #3 and Combination Tylenol and Ibuprofen in Laparoscopic Cholecystectomy, Inguinal Hernia and Abdominal Hernia, sponsored by Nova Scotia Health Authority. Completed at 1 site in Canada. Open to participants aged 17 Years to 65 Years. Per ClinicalTrials.gov, last updated 2008-04-01.

Sponsored by Nova Scotia Health Authority · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
17 Years to 65 Years
Sex
All
01

Study summary

Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen.

Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument.

The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day).

This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free.

The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.

02

Conditions studied

  • Laparoscopic Cholecystectomy
  • Inguinal Hernia
  • Abdominal Hernia
  • Umbilical Hernia

Keywords

  • Outpatient Surgery for:
  • inguinal hernia repair
  • abdominal hernia repair
  • umbilical hernia repair
03

In context

Hernia, Umbilical

67 studies on the registry are indexed under Hernia, Umbilical; 13 are open to participants now.

This study's enrollment of 150 is above the median of 70 across 39 interventional studies indexed under Hernia, Umbilical.

Browse Hernia, Umbilical studies →

Lead sponsor

Nova Scotia Health Authority is the lead sponsor of 255 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Patients may take part in this study if the answer is YES to all of these questions:

  • Female or male between 17-65 years of age
  • Going to have one of the following surgeries:

    • umbilical hernia repair
    • inguinal hernia repair
    • small incisional or abdominal wall hernia repair
    • laparoscopic cholecystectomy (gallbladder removed)
  • Going home after their surgery the same day
  • Have signed consent form.

Exclusion criteria

Exclusion Criteria:

Patients have had or have:

  • Been diagnosed with peptic ulcer disease or bleeding stomach ulcer in the recent past and are not currently on a proton pump inhibitor (special antacid medication, eg. Losec®, Pantoloc®, Prevacid®, Nexium®).
  • Suffered from asthma
  • Allergies to codeine, non-steroidal anti-inflammatory drugs (Advil®, Ibuprofen), aspirin, or acetaminophen
  • Been taking other prescription pain medications prior to their surgery
  • A history of chronic pain disorder
  • Fibromyalgia (a chronic pain illness with symptoms of muscle aches, pain, stiffness, general fatigue and sleep problems)
  • Active kidney disease or failure
  • Known liver disease
  • Are females who are pregnant or nursing
  • A problem with alcohol or drug abuse.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
150 participants

Interventions

  • DrugTylenol #3
  • DrugCombination Tylenol and Ibuprofen
06

What researchers measure

Primary outcomes

  1. Mean daily and final visual analog scale (VAS) scores

  2. Mean daily and final Likert scores

  3. Total pain relief

  4. Sum of pain intensity differences

  5. Cumulative weekly VAS scores

Secondary outcomes

  1. Treatment failures

  2. Amount of medication used

  3. Days to stopping medication

  4. Incidence of side effects

  5. Compliance with regimen

07

Study locations

1 site
  • Dartmouth General Hospital
    Dartmouth, Nova Scotia B2Y 4G8, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 1, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00245375
Lead sponsor
Nova Scotia Health Authority
Collaborators
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
First posted
Oct 28, 2005
Start date
Jan 2005
Completion
Dec 2005
Last update
Apr 1, 2008

Study contacts

Geoffrey A Porter, MD, FRCSC
study director · CDHA/Dalhousie University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion